The end of AIDS: HIV infection as a chronic disease

The Lancet

Volumn 382, Issue 9903, 2013, Pages 1525-1533

  Deeks, Steven G ^a   Lewin, Sharon R ^b,c   Havlir, Diane V ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b MONASH UNIVERSITY   (Australia)

^c BURNET INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; NEOPLASM; PATIENT CARE; PRIORITY JOURNAL; REVIEW;

EID: 84886790685     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61809-7     Document Type: Review

References (99)

1. Johnson LF, Mossong J, Dorrington RE, et al, and the International Epidemiologic Databases to Evaluate AIDS Southern Africa Collaboration. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med 2013; 10: e1001418.
2. Nakagawa F, May M, Phillips A. Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis 2013; 26: 17-25.
3. Fauci AS, Folkers GK. Toward an AIDS-free generation. JAMA 2012; 308: 343-44.
4. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52: 793-800.
5. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52: 793-800.
6. Piot P, Quinn TC. Response to the AIDS pandemic-A global health model. N Engl J Med 2013; 368: 2210-18.
7. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173: 614-22.
8. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defi c Syndr 2003; 33: 506-12.
9. Hirschhorn LR, Kaaya SF, Garrity PS, Chopyak E, Fawzi MC. Cancer and the 'other' noncommunicable chronic diseases in older people living with HIV/AIDS in resource-limited settings: a challenge to success. AIDS 2012; 26 (suppl 1): S65-75.
10. Wester CW, Koethe JR, Shepherd BE, et al. Non-AIDS-defi ning events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting. AIDS 2011; 25: 1471-79.
11. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197-223.
12. Bloomfi eld GS, Hogan JW, Keter A, et al. Hypertension and obesity as cardiovascular risk factors among HIV seropositive patients in Western Kenya. PLoS One 2011; 6: e22288.
13. Baker JV, Peng G, Rapkin J, et al, and the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22: 841-48.
14. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51: 435-47.
15. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67.
16. Armah KA, McGinnis K, Baker J, et al. HIV status, burden of comorbid disease and biomarkers of infl ammation, altered coagulation and monocyte activation. Clin Infect Dis 2012; 55: 126-36.
17. Ryom L, Mocroft A, Kirk O, et al, and the D:A:D Study Group. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis 2013; 207: 1359-69.
18. Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012;26: 867-75.
19. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodefi ciency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187: 1534-43.
20. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of infl ammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201: 1788-95.
21. Kuller LH, Tracy R, Belloso W, et al, and the INSIGHT SMART Study Group. Infl ammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203.
22. Sandler NG, Wand H, Roque A, et al, and the INSIGHT SMART Study Group. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203: 780-90. www.thelancet.com Vol 382 November 2, 2013
23. Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcifi ed coronary plaque in HIV-infected patients. J Infect Dis 2011; 204: 1227-36.
24. Baker JV, Huppler Hullsiek K, Singh A, et al. Monocyte activation, but not T cell activation, predicts progression of coronary artery calcium in a contemporary HIV cohort. 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013); Atlanta, GA, USA; March, 2013. 66LB (abstr).
25. Battegay M, Nütsch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006; 6: 280-87.
26. Favre D, Mold J, Hunt PW, et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2010; 2: 32ra6.
27. Doitsh G, Cavrois M, Lassen KG, et al. Abortive HIV infection mediates CD4 T cell depletion and infl ammation in human lymphoid tissue. Cell 2010; 143: 789-801.
28. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197: 126-33.
29. Hatano H, Jain V, Hunt PW, et al. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis 2013; 208: 50-56.
30. Srinivasula S, Lempicki RA, Adelsberger JW, et al. Diff erential eff ects of HIV viral load and CD4 count on proliferation of naive and memory CD4 and CD8 T lymphocytes. Blood 2011; 118: 262-70.
31. Hunt PW, Cao HL, Muzoora C, et al. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS 2011; 25: 2123-31.
32. Ford ES, Greenwald JH, Richterman AG, et al. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS 2010; 24: 1509-17.
33. Justice AC, Freiberg MS, Tracy R, et al. Does an index composed of clinical data refl ect eff ects of infl ammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis 2012; 54: 984-94.
34. Funderburg NT, Mayne E, Sieg SF, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood 2010; 115: 161-67.
35. Pandrea I, Cornell E, Wilson C, et al. Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. Blood 2012; 120: 1357-66.
36. Baker JV, Brummel-Ziedins K, Neuhaus J, et al, and the INSIGHT SMART Study Team. HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation. J Am Heart Assoc 2013; 2: e000264.
37. Rajasuriar R, Khoury G, Kamarulzaman A, French MA, Cameron PU, Lewin SR. Persistent immune activation in chronic HIV infection: do any interventions work? AIDS 2013; 27: 1199-208.
38. Buzón MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are aff ected by raltegravir intensifi cation of HAART-suppressed subjects. Nat Med 2010; 16: 460-65.
39. Hatano H, Strain MC, Scherzer R, et al. Increase in 2-LTR circles and decrease in D-dimer after raltegravir intensifi cation in treated HIV-infected patients: a randomized, placebo-controlled trial. J Infect Dis 2013; published online Aug 23. DOI:10.1093/infdis/ jit453.
40. Hunt PW, Martin JN, Sinclair E, et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis 2011; 203: 1474-83.
41. Gonzalez VD, Falconer K, Blom KG, et al. High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodefi ciency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol 2009; 83: 11407-11.
42. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-71.
43. Byakwaga H, Kelly M, Purcell DF, et al, and the CORAL Study Group. Intensifi cation of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. J Infect Dis 2011; 204: 1532-40.
44. Gori A, Rizzardini G, Van't Land B, et al. Specifi c prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized tral. Mucosal Immunol 2011; 4: 554-63.
45. Cahn P, Ruxrungtham K, Gazzard B, et al. The immunomodulatory nutritional intervention NR100157 reduced CD4+ T-cell decline and immune activation: a 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (the BITE Study). Clin Infect Dis 2013; 57: 139-46.
46. Zeng M, Smith AJ, Wietgrefe SW, et al. Cumulative mechanisms of lymphoid tissue fi brosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest 2011; 121: 998-1008.
47. Moore RD, Bartlett JG, Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS One 2011; 6: e21843.
48. Ganesan A, Crum-Cianfl one N, Higgins J, et al. High dose atorvastatin decreases cellular markers of immune activation without aff ecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis 2011; 203: 756-64.
49. Levy Y, Lacabaratz C, Weiss L, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009; 119: 997-1007.
50. Abrams D, L?y Y, Losso MH, et al, and the INSIGHT-ESPRIT Study Group, and the SILCAAT Scientifi c Committee. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361: 1548-59.
51. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338: a3172.
52. Tate JP, Justice AC, Hughes MD, et al. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS 2013; 27: 563-72.
53. Clegg A, Young J, Iliff e S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet 2013; 381: 752-62.
54. Tinetti ME, McAvay GJ, Chang SS, et al. Contribution of multiple chronic conditions to universal health outcomes. J Am Geriatr Soc 2011; 59: 1686-91.
55. Justice AC. HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep 2010; 7: 69-76.
56. Fried LP, Tangen CM, Walston J, et al, and the Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56: M146-56.
57. Fried LP, Xue QL, Cappola AR, et al. Nonlinear multisystem physiological dysregulation associated with frailty in older women: implications for etiology and treatment. J Gerontol A Biol Sci Med Sci 2009; 64: 1049-57.
58. Barzilay JI, Blaum C, Moore T, et al. Insulin resistance and infl ammation as precursors of frailty: the Cardiovascular Health Study. Arch Intern Med 2007; 167: 635-41.
59. Desquilbet L, Jacobson LP, Fried LP, et al, and the Multicenter AIDS Cohort Study. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci 2007; 62: 1279-86.
60. Erlandson KM, Allshouse AA, Jankowski CM, et al. Association of functional impairment with infl ammation and immune activation in HIV type 1-infected adults receiving eff ective antiretroviral therapy. J Infect Dis 2013; 208: 249-59.
61. Piggott DA, Muzaale AD, Mehta SH, et al. Frailty, HIV infection, and mortality in an aging cohort of injection drug users. PLoS One 2013; 8: e54910.
62. Shah K, Hilton TN, Myers L, Pinto JF, Luque AE, Hall WJ. A new frailty syndrome: central obesity and frailty in older adults with the human immunodefi ciency virus. J Am Geriatr Soc 2012; 60: 545-49.
63. Walston J, Hadley EC, Ferrucci L, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging research conference on frailty in older adults. J Am Geriatr Soc 2006; 54: 991-1001.
64. Brown TT, Glesby MJ. Management of the metabolic eff ects of HIV and HIV drugs. Nat Rev Endocrinol 2012; 8: 11-21.
65. Leeansyah E, Cameron PU, Solomon A, et al. Inhibition of telomerase activity by human immunodefi ciency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis 2013; 207: 1157-65.
66. Payne BA, Wilson IJ, Hateley CA, et al. Mitochondrial aging is accelerated by anti-retroviral therapy through the clonal expansion of mtDNA mutations. Nat Genet 2011; 43: 806-10.
67. Appay V, Fastenackels S, Katlama C, et al. Old age and anticytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. AIDS 2011; 25: 1813-22.
68. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodefi ciency virus care in the United States. Med Care 2006; 44: 990-97.
69. Hall HI, Frazier EL, Rhodes P, et al. Diff erences in human immunodefi ciency virus care and treatment among subpopulations in the United States. JAMA Intern Med 2013; 173: 1337-44.
70. Levitt NS, Steyn K, Dave J, Bradshaw D. Chronic noncommunicable diseases and HIV-AIDS on a collision course: relevance for health care delivery, particularly in low-resource settings-insights from South Africa. Am J Clin Nutr 2011; 94: 1690S-96S.
71. Maher D, Smeeth L, Sekajugo J. Health transition in Africa: practical policy proposals for primary care. Bull World Health Organ 2010; 88: 943-48.
72. Mills EJ, Ford N. Political lessons from the global HIV/AIDS response to inform a rapid noncommunicable disease response. AIDS 2012; 26: 1171-73.
73. Rabkin M, Nishtar S. Scaling up chronic care systems: leveraging HIV programs to support noncommunicable disease services. J Acquir Immune Defi c Syndr 2011; 57 (suppl 2): S87-90.
74. Balabanova D, Mills A, Conteh L, et al. Good health at low cost 25 years on: lessons for the future of health systems strengthening. Lancet 2013; 381: 2118-33.
75. Samb B, Desai N, Nishtar S, et al. Prevention and management of chronic disease: a litmus test for health-systems strengthening in low-income and middle-income countries. Lancet 2010; 376: 1785-97.
76. Duncombe C, Ball A, Passarelli C, Hirnschall G. Treatment 2.0: catalyzing the next phase of treatment, care and support. Curr Opin HIV AIDS 2013; 8: 4-11.
77. Virga PH, Jin B, Thomas J, Virodov S. Electronic health information technology as a tool for improving quality of care and health outcomes for HIV/AIDS patients. Int J Med Inform 2012; 81: e3945.
78. Bärnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, Newell ML. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect Dis 2011; 11: 942-51.
79. Callaghan M, Ford N, Schneider H. A systematic review of taskshifting for HIV treatment and care in Africa. Hum Resour Health 2010; 8: 8.
80. Ford N, Mills EJ. Simplifi ed ART delivery models are needed for the next phase of scale up. PLoS Med 2011; 8: e1001060.
81. Roberts T, Bygrave H, Fajardo E, Ford N. Challenges and opportunities for the implementation of virological testing in resource-limited settings. J Int AIDS Soc 2012; 15: 17324.
82. Heidari S, Mofenson L, Cotton MF, Marlink R, Cahn P, Katabira E. Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential eff ects on HIV-exposed but uninfected children. J Acquir Immune Defic Syndr 2011; 57: 290-96.
83. Bendavid E, Ford N, Mills EJ. HIV and Africa's elderly: the problems and possibilities. AIDS 2012; 26 (suppl 1): S85-91.
84. Bor J, Herbst AJ, Newell ML, Bärnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 2013; 339: 961-65.
85. Hontelez JA, Lurie MN, Newell ML, et al. Ageing with HIV in South Africa. AIDS 2011; 25: 1665-67.
86. Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PLoS One 2013; 8: e55824.
87. WHO. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. Geneva: World Health Organization, 2012.
88. Geneau R, Hallen G. Toward a systemic research agenda for addressing the joint epidemics of HIV/AIDS and noncommunicable diseases. AIDS 2012; 26 (suppl 1): S7-10.
89. Rabkin M, Melaku Z, Bruce K, et al. Strengthening health systems for chronic care: leveraging HIV programs to support diabetes services in Ethiopia and Swaziland. J Trop Med 2012; 2012: 137460.
90. van Olmen J, Schellevis F, Van Damme W, Kegels G, Rasschaert F. Management of chronic diseases in Sub-Saharan Africa: crossfertilisation between HIV/AIDS and diabetes care. J Trop Med 2012; 2012: 349312.
91. Sambo LG, Kirigia JM. Africa's health: could the private sector accelerate the progress towards health MDGs? Int Arch Med 2011; 4: 39.
92. Deeks SG, Autran B, Berkhout B, et al, and the International AIDS Society Scientifi c Working Group on HIV Cure. Towards an HIV cure: a global scientifi c strategy. Nat Rev Immunol 2012; 12: 607-14.
93. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confi rm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9: 727-28.
94. Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360: 692-98.
95. Yukl SA, Boritz E, Busch M, et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog 2013; 9: e1003347.
96. Henrich TJ, Hu Z, Li JZ, et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013; 207: 1694-702.
97. Persaud D, Gay H, Ziemniak C, et al. Functional HIV cure after very early ART of an HIV infected infant. 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013); Atlanta, GA, USA; March, 2013. 48LB (abstr).
98. Sáez-Cirión A, Bacchus C, Hocqueloux L, et al, and the ANRS VISCONTI Study Group. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9: e1003211.
99. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487: 482-85.